MedTrace Logo

Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus

NCT05179018 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-02-24

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by production of autoantibodies directed against nuclear and cytoplasmic antigens. Clinically, this disorder is characterized by periods of remission and relapse (1). The early and accurate diagnosis of SLE is challenging (2).

The SLE pathogenesis involves multiple cellular components of the innate and immune systems, presence of autoantibodies and immune complexes, engagement of the complement system and cytokine dysregulation (3). About 180 autoantibodies have been identified in SLE patients, 102 of which are reported to have an organ-specific correlation with SLE disease identified in SLE patients, with SLE disease activity (4). However, with the exception of autoantibodies such as antinuclear antibody (ANA), anti double stranded DNA (dsDNA), anti-smith and antiphospholipid antibodies, currently proposed by the American college of rheumatology (ACR) (5)

Conditions

Interventions

DIAGNOSTIC_TEST

Ribosomal p2 Autoantibodies as a Serum marker

Using serum marker

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Samar Hassanein goma, MD · Assiut university Egypt

  • Maha Sayed ibrahim, MD · Assiut university Egypt

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-10-01
Completion
2023-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179018 on ClinicalTrials.gov